Islet Sciences, Inc., a wholly-owned subsidiary of One E-Commerce Corporation (OTC.BB: ONCED), a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has named George J. Todaro, M.D. and Jerry L. Nadler, M.D. to its Board of Directors. Dr. Todaro and Dr. Nadler join Joel D.
Perlin, Dr. Jonathan Lakey and John Steel to the company's Board of Directors.
A renowned research scientist and medical doctor, George Todaro co-authored the groundbreaking "Oncogene Theory" while at the National Institute of Health (NIH) in 1969, which would serve as one of the foundations for future cancer research. In the early 1990s, as scientific director at Seattle-based PathoGenesis, he developed a treatment that has saved the lives of countless cystic fibrosis patients. His most recent focus is biotechnology, where he is working on ways to increase the world's food supply. Dr. Todaro is a member of the National Academy of Sciences, holds over 20 patents and has served as professor and department head at the University of Washington.
Dr. Jerry L. Nadler is Professor and Chairman of Internal Medicine, the Harry H. Mansbach Endowed Chair in Internal Medicine and Director of the Strelitz Diabetes Center at Eastern Virginia Medical School.
He is also the Scientific Founder of DiaKine, a company developing therapies for type 1 and type 2 diabetes and related complications.
Currently, Dr. Nadler serves as a Pfizer Visiting Professor in Diabetes. Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the National Institutes of Health Diabetes Institute and was the Associate Director of the NIH-funded Diabetes Endocrinology Research Center at the University of Virginia. Dr.
Nadler has research funding from the Juvenile Diabetes Foundation, The Ella Fitzgerald Charitable Foundation and the Iacocca Foundation. He is a standing member of the ADA and NIH grant review committees.
"George and Jerry bring distinctively different but equally important skill sets to our Board," said John Steel, Chairman and CEO of Islet Sciences. "George's wealth of experience and success in researching and discovering real-world treatments for cancer and cystic fibrosis are a perfect fit for our company as Islet Sciences works toward a practical treatment for diabetes. Jerry brings not only the academic's perspective but also the knowledge and insights gained as an involved scientific founder for diabetes therapies as well as an active member or director to several esteemed institutions. I look forward to their counsel and expertise in driving the success of Islet Sciences." About Islet Sciences, Inc. Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.
The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the companies' successful execution of their perspective business strategies, including with respect to the successful development of cell therapeutics, including with respect to Islet Sciences -as well as the future of the cell therapeutics industry. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements on September 30, 2011 and for Islet include the risks described in the One E-Commerce Corporation Form 8-K filed with the Securities and Exchange Commission on December 30, 2011. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.
Investor Contact: Jeff Ramson ProActive Capital Resources Group (646) 863-6341 firstname.lastname@example.org SOURCE Islet Sciences, Inc.
-0- 03/06/2012 (OTC-BB:ONCED) / CO: Islet Sciences, Inc.
ST: New York IN: HEA BIO MTC OTC SU: PER PRN -- NY65181 -- 0000 03/06/2012 14:00:00 EDT http://www.prnewswire.c